Paper - WANFANG MED ONLINE

You Position: Home > Paper

中国胰腺外分泌功能不全诊治规范(草案)

( views:58, downloads:457 )

Author:: No author available

Journal Title:: Chinese Journal of Pancreatology

Issue:: 1

DOI:: 10.3760/cma.j.issn.1674-1935.2013.01.016

Key Word:: No keyword available

Abstract：为规范我国胰腺外分泌功能不全的临床诊治,由《中华胰腺病杂志》编委会牵头,经内科、外科和营养等多学科专家共同讨论,拟定本规范,供临床诊疗参考.胰腺是仅次于肝脏的人体第二大外分泌器官,兼有内分泌和外分泌功能.其中外分泌部分由腺泡、导管和间质3个部分组成,腺泡是合成、储存和分泌胰酶的部位,导管的主要功能是分泌水和电解质,也是输送胰液的通道.胰酶在大分子营养物质的消化中起关键作用.

Reference

[1]周继盛.胰腺外分泌不足的发病机制及胰酶治疗[J].2008,(9).
[2]吴德卿,王兴鹏.急性胰腺炎后胰腺功能和形态变化的研究现状[J].2009,(8).
[3]吴德卿,王兴鹏.胰腺外分泌功能间接测定方法的临床价值与意义[J].2008,(12).
[4]祝喜萍,任旭,张彬彬.胰腺外分泌功能与胰腺癌分期、肿瘤大小关系的临床研究[J].2008,(4).
[5]刘瑞,唐岩.外科领域中胰腺外分泌功能不全的诊治[J].2004,(12).
[6]《中华胰腺病杂志》编委会,中华医学会消化内镜学分会.慢性胰腺炎诊治指南（2012,上海）[J].2012,(3).
[7]徐雅萍,曾悦,王兴鹏.急性胰腺炎后胰腺外分泌功能研究概况[J].2009,(8).
[8]得每通临床协作组.得每通用于胰腺外分泌功能不足133例临床观察[J].2007,(8).
[9]朱晋国,任建安.胰腺外分泌不足病人的胰酶替代治疗[J].2006,(6).
[10]J Enrique, Domínguez-Mu?oz.Pancreatic exocrine insufficiency: diagnosis and treatment.[J].2011,26 Suppl 2.
[11]Graff GR,Maguiness K,McNamara.Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period cros[J].2010,32(1).
[12]E P, DiMagno,V L, Go,W H, Summerskill.Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency.[J].1973,288.
[13]Affronti J.Chronic pancreatitis and exocrine insufficiency.[J].2011,38(3).
[14]Philippe, Lévy,Marc, Barthet,Bruno Richard, Mollard,etc.Estimation of the prevalence and incidence of chronic pancreatitis and its complications.[J].1900,30.
[15]Peter Layer,Hironori Yamamoto,Ludwig Kalthoff,etc.The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis[J].1994,107(5).
[16]Colombo C,Russo MC,Fredella C.Efficacy and tolerability of creon for children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.[J].2009,38(6).
[17]Kuhn RJ,Wier HA.Pancreatic enzyme supplementation.[J].2011,23(5).
[18]Maguiness K,Graff G,Trapnell BC.Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.[J].2009,8(6).
[19]Gubergrits N,Malecka Panas E,Lehman GA,etc.A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.[J].2011,33(10).
[20]Biankin AV,Wilson JS,Wray NH,etc.Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations.[J].2010,193(8).
[21]Dominguez-Munoz JE.Pancreatic enzyme therapy for pancreatic exocrine insufficiency.[J].2007,9(2).
[22]Royall J,Caras S,Graff GR,etc.Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.[J].2010,30(6).
[23]Kuhn RJ,Caras S,Gelrud A,etc.CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.[J].2010,27(12).
[24]Dehoorne Smith ML,Kale Pradhan PB,Giuliano CA.Pancreatic enzyme products: digesting the changes.[J].2011,45(5).
[25]Lohr JM,Hummel FM,Pirilis KT.Properties of different pancreatin preparations used in pancreatic exocrine insufficiency.[J].2009,21(9).